The Integrin Beta 1 pipeline drugs market research report outlays comprehensive information on the Integrin Beta 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Integrin Beta 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Gastrointestinal, Ophthalmology, and Genetic Disorders which include the indications Solid Tumor, Triple-Negative Breast Cancer (TNBC), Primary Sclerosing Cholangitis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Wet (Neovascular / Exudative) Macular Degeneration, Keratoconjunctivitis Sicca (Dry Eye), and Duchenne Muscular Dystrophy. It also reviews key players involved in Integrin Beta 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Integrin Beta 1 pipeline targets constitutes close to 25 molecules. Out of which, approximately 21 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 3, 11, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 4 molecule.
Integrin Beta 1 overview
Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.
For a complete picture of Integrin Beta 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
